PTCHF
PureTech Health plc
OTC Markets OTCPKUSDEQUITY
DELAYED
Sell
-46/100
Last price
1.51
▼ 0.03 (2.01%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
1.54
Day high
1.80
Day low
1.80
Volume
4.86K
Market cap
—
P/E (TTM)
—
52W range
1.45 – 1.92
Trailing performance
Returnvs SPY
1W
-2.01%
-3.9%
1M
-3.51%
-5.0%
3M
-5.45%
-8.8%
6M
-2.58%
-17.6%
YTD
-11.44%
-25.4%
1Y
-20.53%
-36.3%
3Y
-31.98%
-113.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Free account
3 more panels on PTCHF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $4.66M | $4.32M | $750.00K | $2.09M | +8.0% |
| Operating revenue | $4.66M | $4.32M | $750.00K | $2.09M | +8.0% |
| Research & development | $45.74M | $54.28M | $73.73M | $111.29M | -15.7% |
| Selling, general & admin | $20.65M | $27.49M | $25.18M | $31.60M | -24.9% |
| Total operating expense | $103.18M | $140.41M | $146.95M | $199.90M | -26.5% |
| Operating income | -$98.53M | -$136.09M | -$146.20M | -$197.81M | +27.6% |
| Net interest income | -$32.73M | $12.63M | $2.52M | $1.85M | -359.1% |
| Pre-tax income | -$110.93M | $23.77M | -$36.10M | -$92.78M | -566.6% |
| Tax provision | -$842.00K | -$4.01M | $30.52M | -$55.72M | +79.0% |
| Net income | -$109.74M | $53.51M | -$65.70M | -$50.35M | -305.1% |
| Net income to common | -$109.74M | $53.51M | -$65.70M | -$50.35M | -305.1% |
| Basic EPS | -0.46 | 0.21 | -0.24 | -0.18 | -319.0% |
| Diluted EPS | -0.46 | 0.21 | -0.24 | -0.18 | -319.0% |
| EBIT | -$65.15M | $33.81M | -$22.61M | -$88.83M | -292.7% |
| EBITDA | -$61.80M | $37.38M | -$17.68M | -$79.94M | -265.3% |
| Basic shares | 240.79M | 254.46M | 276.30M | 284.76M | -5.4% |
| Diluted shares | 240.79M | 256.03M | 276.30M | 284.76M | -6.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $252.47M | $280.64M | $191.08M | $149.87M | — | -10.0% |
| Cash & short-term investments | $277.30M | $367.31M | $327.14M | $350.10M | — | -24.5% |
| Accounts receivable | $1.76M | $1.52M | $2.38M | $11.87M | — | +15.5% |
| Total current assets | $305.02M | $386.26M | $347.20M | $386.19M | — | -21.0% |
| Property, plant & equipment | $11.50M | $15.13M | $19.36M | $37.24M | — | -24.0% |
| Goodwill & intangibles | $601.00K | $601.00K | $906.00K | $831.00K | — | 0.0% |
| Total assets | $534.71M | $602.63M | $693.97M | $702.65M | — | -11.3% |
| Total current liabilities | $46.31M | $41.39M | $51.37M | $96.89M | — | +11.9% |
| Current debt | $4.92M | $4.11M | $3.70M | $7.50M | — | +19.6% |
| Long-term debt | — | — | $0 | $10.24M | $14.26M | — |
| Total debt | $19.59M | $22.36M | $25.34M | $46.87M | — | -12.4% |
| Total liabilities | $229.03M | $194.70M | $235.74M | $155.06M | — | +17.6% |
| Retained earnings | -$77.23M | $32.49M | $83.82M | $149.52M | — | -337.7% |
| Shareholder equity | $312.07M | $414.71M | $464.07M | $542.22M | — | -24.7% |
| Working capital | $258.71M | $344.87M | $295.83M | $289.31M | — | -25.0% |
| Net tangible assets | $311.47M | $414.11M | $463.16M | $541.39M | — | -24.8% |
| Shares issued | 257.93M | 257.93M | 289.47M | 289.16M | — | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$110.08M | $27.78M | -$66.63M | -$37.06M | -496.2% |
| Depreciation & amortisation | $3.35M | $3.57M | $4.93M | $8.89M | -6.2% |
| Stock-based compensation | $8.22M | $22.85M | $4.42M | $14.70M | -64.0% |
| Change in working capital | -$3.12M | -$10.24M | $17.52M | $15.92M | +69.5% |
| Operating cash flow | -$85.13M | -$134.37M | -$105.92M | -$178.79M | +36.6% |
| Capital expenditure | -$6.00K | -$11.00K | -$245.00K | -$2.18M | +45.5% |
| Investing cash flow | $63.29M | $240.89M | $68.99M | -$107.22M | -73.7% |
| Share buybacks | -$2.05M | -$107.56M | -$19.65M | -$26.49M | +98.1% |
| Financing cash flow | -$6.33M | -$16.96M | $78.14M | -$29.83M | +62.7% |
| Free cash flow | -$85.14M | -$134.38M | -$106.16M | -$180.97M | +36.6% |
| End cash position | $252.47M | $280.64M | $191.08M | $149.87M | -10.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2026-06-30 | 2025-12-31 | 2025-06-30 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $121.28M | $252.47M | $260.60M | -52.0% |
| Cash & short-term investments | $221.36M | $277.30M | $321.55M | -20.2% |
| Accounts receivable | $2.14M | $1.76M | $2.49M | +21.6% |
| Total current assets | $252.32M | $305.02M | $344.39M | -17.3% |
| Property, plant & equipment | $9.85M | $11.50M | $13.31M | -14.3% |
| Goodwill & intangibles | $201.00K | $601.00K | $601.00K | -66.6% |
| Total assets | $637.28M | $534.71M | $553.24M | +19.2% |
| Total current liabilities | $54.86M | $46.31M | $40.58M | +18.5% |
| Current debt | $5.38M | $4.92M | $4.50M | +9.3% |
| Total debt | $18.30M | $19.59M | $20.92M | -6.5% |
| Total liabilities | $257.79M | $229.03M | $184.22M | +12.6% |
| Retained earnings | -$9.98M | -$77.23M | -$12.10M | +87.1% |
| Shareholder equity | $386.23M | $312.07M | $375.98M | +23.8% |
| Working capital | $197.46M | $258.71M | $303.81M | -23.7% |
| Net tangible assets | $386.03M | $311.47M | $375.37M | +23.9% |
| Shares issued | 257.93M | 257.93M | 257.93M | 0.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.54
-1.81% from price
SMA 20
1.59
-5.30% from price
SMA 50
1.57
-4.04% from price
SMA 100
1.64
-7.78% from price
SMA 200
1.67
-9.36% from price
EMA 12
1.55
-2.85% from price
EMA 26
1.57
-4.03% from price
EMA 50
1.59
-4.94% from price
RSI (14)
19.2
Oversold
MACD (12,26,9)
-0.02
Hist -0.01
ATR (14)
0.01
0.97% of price
Realised vol 30D
25.9%
Annualised
Bollinger upper
1.71
20, 2σ
Bollinger lower
1.48
20, 2σ
50 / 200 cross
Death
1.57 vs 1.67
Trend bias
Below 200
-9.36%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.06
Less volatile than market
Correlation to SPY
0.02
Largely independent
Realised vol 30D
25.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-21.4%
Peak to trough
Max drawdown 5Y
-74.6%
Peak to trough
ATR 14
0.01
0.97% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance
Business Wire · 6h ago
PureTech Health gets Panmure Liberum ‘buy’ on value and cash returns
Proactive · 9h ago
Celea Therapeutics Presents SURPASS-IPF Phase 3 Trial Design and Statistical Considerations for Evaluating Clinical Trials in Idiopathic Pulmonary Fibrosis at the IPF Summit 2026
Business Wire · 7d ago
PureTech Health PLC (PTCHF) (H1 2026) Earnings Call Highlights: Cash Runway to 2028, Seaport's ...
GuruFocus.com · 15d ago
PureTech Health H1 Earnings Call Highlights
MarketBeat · 16d ago
PureTech Announces Successful End-of-Phase 1 Meeting with U.S. Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS)
Business Wire · 17d ago
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
Business Wire · 28d ago
PureTech Health: Notice of Half-Yearly Results
Business Wire · 34d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.